Advertisement
Advertisement

Read Now: News and Research From ICAAC 2014

Associations Between Tenofovir Use and Renal Complications in VA Cohort

May/June 2012

 1  |  2  |  Next > 

Tenofovir is one of the most widely used antiretrovirals and the association with a generally low risk of renal complications has been widely reported. However, there has been conflicting data on potential for renal complications with cumulative use or in patients with normal renal function.

An analysis from the U.S. Veterans Association (VA) cohort published in the 24 April 2012 edition of AIDS reported that cumulative use of tenofovir was associated with renal complications and that this might not be reversible.1

From 1997-2007, more than 19,700 treatment naive patients were reported as starting ART in the VA cohort. Discounting those without at least one of the key parameters: CD4, viral load, out-patient visit, renal markers or with renal failure however, reduced this study to 10,841 patients, 4,303 of whom used tenofovir. An era-of-use analysis adjusted for tenofovir not being approved until 2001: 85% of patients used tenfovir in the period 2005-07; 54% in 2003-05 and 17% prior to 2003).

Changes in renal function were determined by one of three criteria.

  1. Proteinuria (urine dipstick ≥30 mg/dL on two consecutive tests).
  2. Rapid decline in kidney function (>3 mL/min/1.73m2 annual decline for at least two years), and
  3. Chronic kidney disease (CKD) (eGFR < 60 mL/min/1.73m2 on two occasions at least 3 months apart).
Advertisement

Additional sensitivity analyses were also performed for time to events and for more extreme renal dysfunction. Patients with proteinuria or CKD at baseline were excluded from those analyses. Hazard ratios (HR) were calculated adjusting for demographic, time dependent and marginal structural models.

Median age was 46 years (IQR 40-52), and approximately 98% of participants were men. Ethnicity included approximately 50% black, 40% white and 10% other. Median CD4 count and viral load before treatment were approximately 200 (IQR 50-400) cells/mm3 and 60,000 (IQR 15,000-220,000) copies/mL.

Prevalence of comorbid conditions at baseline (in the TDF vs no-TDF groups) included hypertension (38% vs 39%), diabetes (6.8 vs 7.9%), HCV (14 vs 17%), smoking (18% vs 19%) and dyslipidaemia (15% both groups). Renal disease at baseline included approximate median eGFR 96 (IQR 82-114) mL/min per 1.73 m2, with 4.7% vs 7.3% with eGRF <60 mL/min/1.73m2 and 19% vs 21% with proteinuria (>30 mg/dL).

Median follow-up per individual ranged from 3.9 years (for proteinuria) to 5.5 years (for CKD), during which there were 3,400 cases of proteinuria (>38,000 patient years), 3078 of rapid kidney decline (>51,500 PY) and 533 CKD events (>56,400 PY). However, participants using tenofovir only had a median of 1.0 year exposure (IQR 0.5-1.9). Therefore 25% of people providing data used tenofovir for less than 6 months, 50% for less than 12 months and 75% less than 2 years. Maximum tenofovir use was 6.3 years. The summary of events shown in Table 1, published as supplementary information, is important to estimate rates in the tenofovir vs no-tenofovir groups, given that the results are in the main paper are based on hazard ratios.


Table 1: Summary of Events and Person Years (PY) by Exposure to Tenofovir
Outcome Events PY Rate/1,000 PY
Proteinuria
Tenofovir never used 2,646 32,421 81.6
Tenofovir ever used 754 5,711 132.0
Rapid Decline
Tenofovir never used 2,349 43,693 53.8
Tenofovir ever used 729 7,896 92.3
Chronic Kidney Disease
Tenofovir never used 352 46,724 7.5
Tenofovir ever used 181 9,692 18.7


All ARVs were included in the analysis, but only tenofovir had an increased association with all three renal markers, in all three adjusted analyses, see Table 2. In the time dependent analysis (adjusting for ARV use in addition to baseline demographics), each year of exposure to tenofovir was associated with 34% increased risk of proteinuria (95%CI 25-45%, p < 0.0001), 11% increased risk of rapid decline (3-18%, p = 0.0033), and 33% increased risk of CKD (18-51%; p < 0.0001). Controlling for slightly more frequent monitoring in tenofovir users did not affect the results. Pre-existing renal risk factors did not appear to worsen the effects of tenofovir.


Table 2: Association of Tenofovir Exposure With Risk of Kidney Disease Outcomes
  Demographic adjusted model

Hazard ratio (95% CI)

Time dependent Cox model

Hazard ratio (95% CI)

Marginal structural model

Hazard ratio (95% CI)

Cumulative exposure to tenofovir (per year)
Proteinuria 1.30 * (1.22 - 1.37) 1.34 * (1.25 - 1.45) 1.24 * (1.17 - 1.32)
Rapid decline 1.1 * (1.11 - 1.24) 1.11 ** (1.03 - 1.18) 1.16 * (1.09 - 1.23)
CKD 1.44 * (1.30 - 1.60) 1.33 * (1.18 - 1.51) 1.36 * (1.22 - 1.51)
Ever exposure to tenofovir
Proteinuria 1.70 * (1.57 - 1.85) 1.68 * (1.52 - 1.85) 1.51 * (1.36 - 1.66)
Rapid decline 1.51 * (1.39 - 1.64) 1.36 * (1.23 - 1.50) 1.50 * (1.36 - 1.67)
CKD 2.11 * (1.76 - 2.54) 1.71 * (1.38 - 2.12) 1.88 * (1.50 - 2.36)

* all P <0.0001 except ** p=0.0033


Other ARVs showed weaker or inconsistent associations with kidney disease events, notably with ritonavir and lopinavir/r associated with proteinuria, atazanavir with rapid decline and indinavir with CKD. See Table 3.


Table 3: Association of Renal Outcomes With ARV Use
Results Shown Only for ARVs With ≥1 Statistically Significant Outcome
ARV % pts with exposure proteinuria p rapid decline p CKD p
Tenofovir 39.7 1.34 (1.25 - 1.45) <0.0001 1.11 (1.03 - 1.18) 0.0033 1.33 (1.18 - 1.51) <0.0001
AZT 68.3 0.98 (0.93-1.03) 0.42 0.98 (0.93-1.02) 0.29 0.89 (0.81-0.98) 0.020
Efavirenz 49.0 0.94 (0.90-0.99) 0.026 1.01 (0.97-1.05) 0.64 0.88 (0.79-0.98) 0.018
Ritonavir 35.7 1.18 (1.09-1.27) <0.0001 0.96 (0.89-1.04) 0.34 0.97 (0.84-1.14) 0.74
Indinavir 24.6 1.04 (0.99 - 1.09) 0.15 0.99 (0.95-1.04) 0.67 1.16 (1.06-1.27) 0.0019
Atazanavir 17.1 0.93 (0.79-1.08) 0.34 1.22 (1.07-1.40) 0.0035 0.96 (0.77-1.18) 0.69
Lopinavir/r 15.3 0.77 (0.68-0.86) <0.0001 1.05 (0.94-1.17) 0.39 1.21 (0.91-1.60) 0.18
Saquinavir 10.7 0.91 (0.83-0.99) 0.035 1.00 (0.92-1.08) 0.97 0.89 (0.72-1.09) 0.24


The association with tenofovir exposure was consistent across sub groups by age, race, all baseline comorbidities except diabetes and CKD, viral load, CD4 and BMI.

Among those who discontinued tenofovir use, risk of kidney disease events did not appear to increase or decrease during median follow-up of 1.2 years. Previous use of tenofovir was associated with a higher risk of all complications compared to never-use.

 1  |  2  |  Next > 



This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement